StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) company profile

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$12.85−0.07 (-0.54%)

Close on Nov 17, 2026Market cap $171.97MP/E –Yield –

About Anika Therapeutics

Surgical & Medical Instruments & Apparatus, SIC 3841

Anika Therapeutics, Inc. develops and commercializes medical therapies focused on osteoarthritis pain management and regenerative solutions for early intervention orthopedics. Utilizing proprietary hyaluronic acid technology, the company offers pain relief injections such as Orthovisc, Monovisc, and Cingal, alongside regenerative orthopedic implants and bone substitutes including the Integrity system, Hyalofast, and Tactoset. It also supplies non-orthopedic legacy lines, comprising ophthalmic aids, anti-adhesion barriers, and equine treatments. Anika serves healthcare providers across office practices, hospital operating rooms, and ambulatory surgery centers through direct sales, commercial partnerships, and third-party distributors.

The company manufactures its hyaluronic acid product lines at a centralized production facility located in Bedford, Massachusetts. Internationally, its therapies reach global markets through worldwide distributor agreements, with products such as Cingal distributed in more than 50 countries and Hyalofast available across more than 30 nations throughout Europe, South America, and Asia.

Summary of the business section of Anika Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Anika Therapeutics, Inc.
Founded
1992
Headquarters
Bedford, MA
Address
32 Wiggins Avenue 01730
Phone
(781) 457-9000
Website
anika.com
Employees
235, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ANIK
Exchange
Nasdaq
IPO date
May 3, 1993
Shares outstanding
13M, Jul 24, 2026
Public float
$147.34M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
898437
CUSIP
035255108
ISIN
US0352551081
FIGI
BBG000BBKZD8
Share class FIGI
BBG001S609X7
LEI
529900R9LS3Z0O6QH455
EIN
04-3145961

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Stephen D. GriffinPresident and CEO, Director49,742
Ian McLeodSVP, CAO & Treasurer24,888
David ColleranEVP, General Counsel, Corp Sec67,570
Anne NunesSVP, Chief Operations Officer21,722
Gary P. FischettiDirector54,015
Joseph H. CapperDirector30,805
Sheryl L. ConleyDirector52,970
John B. Henneman IiiDirector65,273
Stephen RichardDirector58,273
Cheryl R. BlanchardDirector282,634
William R. JellisonDirector23,103
Glenn R. LarsenDirector50,258
Susan L. N. VogtDirector50,213

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.89M$2.08M$1.34M$21$120
FY2024$5.10M$2.53M$1.81M$36$91
FY2023
Blanchard
$4.46M$1.87M$1.41M$50$92
FY2023
Dr Blanchard
$4.46M$1.87M$1.41M$50$92
FY2022
Blanchard
$5.94M$3.60M$1.74M$65$89
FY2022
Dr Blanchard
$5.94M$3.60M$1.74M$65$89

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Cheryl R. Blanchard, Ph.D.
Executive Chair; Former President and Chief Executive Officer
$750.40K$638.00K$3.48M$22.25K$4.89M-4%
Stephen D. Griffin
President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer
$500.00K$300.00K$1.22M$18.15K$2.03M-23%
David B. Colleran
EVP, General Counsel and Secretary
$486.42K$219.00K$889.62K$19.16K$1.61M-3%
Anne M. Nunes
Former SVP, Chief Operations Officer
$157.64K–$505.92K$282.31K$946.57K-16%
Ian W. McLeod
SVP, Chief Accounting Officer and Treasurer
$345.36K$121.99K$275.94K$22.25K$765.54K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 235 full-time employees in the United States and Europe.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?